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Abstract
Background: Gene therapy and viral therapy are used for cancer therapy for many years, but the results are less
than satisfactory. Our aim was to construct a new recombinant adenovirus which is more efficient to kill
hepatocarcinoma cells but more safe to normal cells.
Methods: By using the Cancer Targeting Gene-Viro-Therapy strategy, Apoptin, a promising cancer therapeutic
gene was inserted into the double-regulated oncolytic adenovirus AD55 in which E1A gene was driven by alpha
fetoprotein promoter along with a 55 kDa deletion in E1B gene to form AD55-Apoptin. The anti-tumor effects and
safety were examined by western blotting, virus yield assay, real time polymerase chain reaction, 3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay, Hoechst33342 staining, Fluorescence-activated cell
sorting, xenograft tumor model, Immunohistochemical assay, liver function analysis and Terminal deoxynucleotidyl
transferase mediated dUTP Nick End Labeling assay.
Results: The recombinant virus AD55-Apoptin has more significant antitumor effect for hepatocelluar carcinoma
cell lines (in vitro) than that of AD55 and even ONYX-015 but no or little impair on normal cell lines. Furthermore,
it also shows an obvious in vivo antitumor effect on the Huh-7 liver carcinoma xenograft in nude mice with bigger
beginning tumor volume till about 425 mm3 but has no any damage on the function of liver. The induction of
apoptosis is involved in AD55-Apoptin induced antitumor effects.
Conclusion: The AD55-Apoptin can be a potential anti-hepatoma agent with remarkable antitumor efficacy as well
as higher safety in cancer targeting gene-viro-therapy system.
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Background
Hepatocellular carcinoma (HCC) is the third most com-
mon cause of cancer death in china and the fifth most
prevalent male cancer worldwide. Routine curative
therapies such as liver transplantation and surgical
resection are offered to only limited patients. Other
treatments include chemotherapy, radiotherapy, thermo-
therapy and so on may be beneficial for unresectable
HCC, but recurrence is frequent and the long term
survival rate remains poor [1]. Therefore, new effective
and efficient therapies are urgently needed.
Gene therapy exhibits a promising advantage for many
diseases such as Leber’s congenital amaurosis, X-linked
adrenoleukodystrophy and"Bubble boy” disease, which
was selected as the one of top ten news in the journal
of “sicence”[2]. However, it is not efficient for cancer
therapy by delivering a single therapeutic gene because
of polygenes related disregulated pathways in cancer
cells. Recently, “Cancer Targeting Gene-Viro-Therapy”
is an attractive strategy for cancer gene therapy, the
principle of which is to insert anti-tumor genes into
oncolytic virus [3]. As oncolytic virus replicating in
tumor cells, the therapeutic gene simultaneously gets
amplification, ultimately exhibits an enhanced effect on
* Correspondence: jdf_ha@yahoo.com.cn
† Contributed equally
3School of Life Sciences, Institutes of Biomedical Sciences, Fudan University,
Shanghai, China
Full list of author information is available at the end of the article
Zhang et al. Journal of Biomedical Science 2012, 19:20
http://www.jbiomedsci.com/content/19/1/20
© 2012 Zhang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.killing tumor cells. Conditional replicative adenoviruse is
mostly used in this strategy by virtue of its ability to
transfer foreign genes efficiently [4] and replicates selec-
tively in cancer cells and destroys them [5]. Basically
two main strategies are used to make their replication
cancer-specific. The first involves deletion of viral genes
that are dispensable in tumor cells but not in normal
cells, such as ONYX-015 or ZD55 [6] which deleted
E1B 55 kDa gene which control the viral mRNA trans-
port [7]. The second is the replacement of viral promo-
ters with tumor or tissue-specific promoters. Paul
Hallenbec [8] have pioneered the efforts in this direction
by using a-fetoprotein (AFP) promoters to drive the
adenovirus E1A gene to treat hepatocellular carcinoma.
AFP is expressed abundantly in fetal liver cells but not
in normal adult liver cells. However, AFP is frequently
re-expressed in HCC and correlated with disease pro-
gression. Approximately over 70% of primary HCC has
actived AFP protein [9]. Due to the specific expression
spectrum of AFP, AFP promoter was extensively used as
hepatocarcinoma targetting promoter to drive the ade-
novirus E1A gene [8,10] or directly drive suicide genes
such as herpes simplex virus thymidine kinase (HSV-tk)
[11,12].
Apoptin, a chicken anemia virus (CAV)-derived pro-
tein, can induce apoptosis in a large panel of human
transformed and malignant cells but not in normal cells
[13]. It shows to be independent of tumor-suppressor
gene p53 [14] and cannot be inhibited by oncogene Bcr-
abl as well as even sometimes stimulated by over
expression of the apoptosis inhibitor Bcl-2 [15-17]. In
short, Apoptin is a promising and ideal agent for cancer
gene therapy owing to its intrinsic specificity and the
inherent low toxicity, although the mechanism has not
yet been fully elucidated. Several studies have already
shown the excellent efficacy and safety of Apoptin in
cancer gene therapy by various ways from using TAT,
PTD4-Apoptin fusion protein [18,19] to recombinant
parvoviruses, adenoviruses and poxviruses directly har-
bored apoptin gene [20-22].
Previous studies in our laboratory have shown excep-
tional merit of Cancer Targeting Gene-Viro-Therapy,
compared to gene therapy or virotherapy alone [23-25],
which uses the conditionally replicating oncolytic adeno-
virus (CRAd) to harbor the antitumor gene and gains
tumor-specific therapeutic effect. In this study, we con-
structed a double regulated CRAd “AD55” with both
E1A gene driven by eAFP promoter (including SV40
enhancer at the upstream of 275 bp alpha-fetoprotein
promoter, abbreviated to “eAFP”) and E1B 55KD dele-
tion, then the Apoptin gene expression cassette under
controlling of human CMV promoter was inserted into
AD55, formed AD55-Apoptin. The in vitro and in vivo
results showed that AD55-Apoptin shows a remarkable
and specific anti-hepatoma effect, furthermore it even
can strongly inhibit the growth of advanced xenograft
tumors with larger volume which always thought can’t
be easily stopped.
Materials and methods
Cell lines and culture conditions
H E K 2 9 3( h u m a ne m b r y o n i ck i d n e yc e l ll i n ec o n t a i n i n g
the E1A region of Ad5) was obtained from Microbix
Biosystem Inc (Toronto, Canada). The HCC cell lines
(HepG2, PLC, Hep3B and Huh-7) were from American
Type Culture Collection (ATCC, Rockville, MD, USA),
the other live cancer cell lines (SMMC-7721, BEL-7404)
and normal liver cell lines(L-02, QSG-7701 and WI38)
were obtained from Shanghai cell collection (shanghai,
china). All these cell lines were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% heatinactivated fetal bovine serum (FBS), 4 mM
glutamine,50 U/ml penicillin and 50 mg/ml streptomy-
cin. All the cell lines cultured condition were at 37°C in
5% CO2.
Construction of the plasmids, generation and purification
of adenovirus vectors
The short fragment of pAd△E1P [26]digested by EcoRI
and XbaI was cloned into pZD55 [6] to form the plas-
mid pAd△E1P-ZD55. The eAFP promoter was amplified
from the plasmid pDRIVE03-SV40enh/AFP(h) v04 (Invi-
voGen Corp, USA; Catalog# pdrive-sv40-hafp), then the
PCR product was subcloned into pAd△E1P-ZD55 by
XhoIa n dSnaB I to form the plasmid pAD55. After
inserting the apoptin expression cassette from pCA13-
apoptin (JieRui biotech Corp, shanghai, China) into it,
the plasmid pAD55-Apoptin was obtained. The oncoly-
tic viruses AD55-Apoptin and AD55-Apoptin were gen-
erated by homologous recombination of either pAD55-
Apoptin or pAD55 and the adenovirus packaging plas-
mid pBHGE3 (Microbix Biosystems, Toronto, ON,
Canada) in HEK293 cells. Each recombinant adenovirus
was isolated through three rounds of plaque purification
in HEK293 cells and purified by ultracentrifugation in a
cesium chloride gradient. Moreover, Virus Titers were
determined by TCID50 assay in HEK293 cells. Cells
were infected with adenovirus at different doses at 37°C
in humidified atmosphere containing 5% CO2.
Cell viability assay
Cells were plated in 96-well plates and treated with var-
ious adenoviruses. After infection for four days with the
indicated multiplicity of infection(MOI), cell survival
rate was evaluated by a standard 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
(Sigma, St Louis, MO), Medium was removed and fresh
medium containing 3-(4,5-dimethylthiazol-2-yl)-2,5-
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Page 2 of 12diphenyltetrazolium bromide (MTT, 5 mg/ml) was
added to each well. The cells were incubated at 37°C for
4 h, after draw off the supernatant of each well carefully
a n dt h e na ne q u a lv o l u m e1 5 0μl of DMSO was added
to each well and mixed thoroughly on concentrating
table for 10 minutes. The absorbance from the plates
w a sr e a da t5 9 5n mw i t haD N AE x p e r tM i c r o p l a t e
Reader Model GENios.
Western blot analysis
To determine the expression of various proteins, Wes-
tern blot analysis was performed as described standard
protocol. Cells were harvested by trypsinization and
resuspended in lysis buffer (62.5 mM Tris-HCl pH 6.8,
2% SDS, 10 mM glycerol, 1.55% dithiothreitol). The
total protein concentration was determined by the
BCA™Protein Assay kit (PIERCE) as described protocol.
Then, protein samples were separated by 10-15% SDS-
polyacrylamide gel electrophoresis and transferred to
nitrocellulose membranes (Millipore). Membranes were
blocked in 5% BSA solution and incubated with primary
antibodies, then detected by the appropriate secondary
fluorescent antibodies and checked out with an Odyssey
Infrared imaging system (LI-COR Biosciences Inc,
America). The primary antibodies used were anti-E1A
(Abcam, Cambridge, UK), and anti-actin (Beyotime, Hai-
men, China).
Real-time quantitative PCR to detect the relative mRNA
level of Apoptin
Huh-7 cells or QSG-7701 cells were seeded in 6-well
culture plates and then infected with AD55 or AD55-
Apoptin at a MOI of 10 for 24, 48 and 96 hours, respec-
tively. The mRNA was collected by using of Trizol at
the indicated time and then reversed-Transcripted into
cDNA (ReverTra Ace, Toyobo). Primers (Apoptin For-
ward primer: ACCATCAACGGTGTTCAGG; Apoptin
Reverse primer: CAGCCACACAGCGATAGAG;
GADPH Forward primer: CATCATCCCTGCCTC-
TACTG; GADPH Reverse primer: GCCTGCTTCAC-
CACCTTC) were used to amplify apoptin or GAPDH
gene according the standard procedures of real time
PCR and obtained the relative mRNA expression level
of the apoptin compared to endogenous GADPH.
Hoechst 33324 staining
HepG2, PLC, Huh-7, WI38 and L-02 cells were seeded in
6-well culture plates and infected with AD55-Apoptin,
A D 5 5a n dO N Y X - 0 1 5a taM O Io f5 ,u n i n f e c t e dc e l l s
served as control. After 48 hours, cells were treated with
the apoptosis-Hoechst 33324 staining kit (Beyotime) for
5-10 min as described protocol, washed with PBS twice,
and observed under a fluorescence microscope.
Flow cytometric analysis
Cells infected with various adenoviruses were trypsinized
and washed once with complete medium. Aliquots of
cells (5 × 10
5) were resuspended in 500 ml of binding
buffer and stained with fluorescein isothiocyanate
(FITC)-labeled annexin V (BioVision, Palo Alto, CA)
according to the manufacturer’s instructions. A fluores-
cence-activated cell-sorting (FACS; BD Biosciences, San
Jose, CA) assay was performed immediately after staining.
Studies on xenograft tumors in nude mice
All animals used in these experiments were maintained
in the institutional facilities in accordance with regula-
tions and standards of the US Department of Agriculture
and the National Institutes of Health. Female BALB/c
nude mice at 4-5 weeks obtained from the Animal
Research Committee of the Institute of Biochemistry and
Cell Biology (Shanghai, China) were used in all of the
experiments. Huh-7 cells (1 × 10
7) were injected subcuta-
n e o u s l yi n t ot h el o w e rr i g h tf l a n ko ff e m a l en u d em i c e .
After about two weeks, tumor xenografts model was
established. Each group was at least comprised of eight
animals and the tumor growth was monitored and mea-
sured with a vernier caliper and tumor volume (V) was
calculated using the formula V (mm
3)=1 / 2×l e n g t h
(mm)×width(mm)
2. When the tumors were about 425
mm
3 in size, mice were randomized into four groups and
ad a i l yd o s eo f3×1 0
8 plaque-forming unit (PFU) of
examined viruses AD55-Apoptin, AD55 and ONYX-015
suspended in 100 μl of PBS or 100 μlP B Sa l o n ew a s
administrated intratumorally once everyday for a total of
five. The tumors were harvested at the fourth day post
treatment with adenovirus for H&E staining, Immunohis-
tochemical study and The TdT-mediated dUTP-biotin
nick end-labeling (TUNEL) staining.
Immunohistochemical (IHC) study
For IHC analysis, tumors on day 4 post-treatment were
harvested and fixed in 4% paraformaldehyde, embedded
in paraffin and cut in 4 um sections. These sections
were stained with goat monoclonal anti-adenoviral
hexon antibody at a 1:200 dilution, respectively. The
slides were then washed with PBS and incubated with
the avidin-biotin-peroxidase complex reagent (Vector
Laboratories, Burlingame, CA) and detected with diami-
nobenzidine tetrahydrochloride [27] solution containing
0.006% hydrogen peroxide. Hematoxylin was used as a
counterstain. Tissue sections stained without primary
antibodies were used as negative controls.
TUNEL apoptosis assay
TUNEL assay was used for detection of apoptotic cells.
For this purpose, the in situ cell apoptosis detection kit
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according to the manufacturer’s procedures. Tissue sec-
tions in PBS group were stained and served as positive
controls. The TUNEL reaction preferentially labels DNA
strand breaks generated during apoptosis, and allows
discrimination of apoptosis from necrosis and primary
DNA strand breaks induced by apoptotic agents.
ALT and AST assay after targeting gene-virus treatment
in nude mice
As for the each treated group(n = 3), after the viruses
were intratumorally injected into nude mice a month
later, the nude mice were killed and collected their
blood through eyeball and liver function was examined
according to the related standard procedures [28].
Statistical analysis
The statistical significance of experimental results was
calculated by analysis of variance (ANOVA) and student
t-test. Datas were considered statistically significant at P
< 0.05.
Results
Construction and characterization of the recombinant
AD55-Apoptin
The dual regulated oncolytic adenovirus AD55 based on
oncolytic adenovirus ZD55 with E1B 55KD deletion was
constructed by using HCC-specific eAFP promoter to
control E1A gene. Then, the antitumor gene Apoptin
w a si n s e r t e di n t oE 1 Br e g i o na n df o r m e dA D 5 5 - A p o p -
tin. The construction of AD55 and AD55-Apoptin were
shown in Figure 1A.
To evaluate the characterization of the constructs, we
detected the tumor-specific expression of adenovirus
E1A by Western blot assay. The normal hepatocelluar
line L-02 and two HCC cell lines Huh-7 and PLC were
infected with ONYX-015, AD55and AD55-Apoptin at a
MOI of 5 for 48 hours, then the E1A protein expression
was detected. The results showed that the dual regulated
oncolytic adenovirus AD55 and AD55-Apoptin only
expressed E1A protein in Huh-7 and PLC HCC cells
but not in L-02 normal cells compared to that of
ONYX-015 with positive expression level, the mock
g r o u pw a sa san e g a t i v ec o n t r o l( F i g u r e1 B ) .I td e m o n -
strated that this dual regulated constructs can specifi-
cally replicates in HCC cells.
To examine whether the transgene and modified gen-
ome of adenovirus could interfere with the selective
replicative ability of recombinant adenoviruses in differ-
ent cell lines, a progeny assay was performed in tumor
cells (BEL7404, PLC, Hep3B, SMMC-7721 and Huh-7)
and normal liver cell lines (L-02, QSG-7701) infected
with different constructs including (ONYX-015, ZD55-
EGFP, AD55 and AD55-Apoptin). As shown in Figure
1C, the above viruses can easily replicate in infected
liver cancer cells with more virus progeny yield com-
pared to the normal liver cells with reduced replicative
capacity. These data indicated that insertion of apoptin
gene and deletion of E1B did not strongly affect the
selective replicative ability of AD55-Apoptin in cancer
cell compared with the vector AD55, although its repli-
cative capacity was different from the other constrcuts.
Moreover, in order to examine the expression of
apoptin gene, real time PCR assay was done after infec-
tion of Huh-7 or QSG-7701 cells with AD55-Apoptin or
AD55 at a MOI of 10 for the indicated hours in Figure
1D. The results indicated that the expression of apoptin
was remarkable time-dependent in Huh-7 cells but not
in normal liver QSG-7701 cells, these data further sup-
ported AD55-Apoptin can selectively target the HCC
cells.
Cytotoxicity of AD55-Apoptin in tumor cells but not in
normal cells
To validate the cytotoxicity of AD55-Apoptin, the HCC
cell lines (Hep3B, PLC and Huh-7) and normal cell lines
(L-02, QSG-7701 and WI38) were infected with indicated
adenovirus at MOI of 0.1, 1, 10 respectively. 4 days later,
cytotoxicity was determined by MTT assay. As shown in
Figure 2A, AD55-Apoptin, AD55 and ONYX-015 all
could induce dose-dependent cytotoxicity in these tumor
cell lines, Nevertheless AD55-Apoptin exhibited higher
cytotoxicity (p < 0.05) than that of AD55 and ONYX-
015, but showed no obvious cytotoxicity to the normal
cell lines compared to ONYX-015 and AD55 (Figure 2B),
although the antitumor effect of the vector AD55 was
not strong than that of ONYX-015. The results suggested
that AD55-Apoptin had an obvious cytotoxic effect on
different hepatocarcinoma cells in vitro but had no or lit-
tle influence on normal cells.
Additionally, the cell-killing effect was also observed
by MTT assay in the indicated time course (Figure 3).
HCC cell lines HepG2, Hep3B, PLC, Huh-7 and normal
cell lines L-02 and WI38 were infected with ONYX-015,
AD55 and AD55-Apoptin at the MOI of 10, respec-
tively. And the antitumor ability and safety were evalu-
ated at day1, 2, 3 and 4. As shown in Figure 3, AD55-
Apoptin displayed much higher toxicity than that of
ONYX-015 and AD55 in HCC cells but no notable toxi-
city in normal cells WI38, although a little bit higher
toxicity than that of AD55 in L-02 cells.
Mechanism of apoptosis induced by AD55-Apoptin in
Huh-7 cells
To further investigate whether AD55-Apoptin killed the
tumor cells through apoptosis, HCC cells (HepG2, PLC
and Huh-7) and normal cells (WI38 and L-02) were
analyzed with apoptotic cells stained by Hoechst 33342
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Page 4 of 12Figure 1 Construction of the dual regulated oncolytic adenovirus AD55-Apoptin and its selective replication in tumor cells. A.
Schematic structure of recombinant adenoviruses. Compared with E1B 55KD-deficient adenovirus ZD55, the dual-regulated adenovirus AD55-
Apoptin had been further modified with both the E1A promoter replaced by eAFP and the E1b55KD deletion. Then, the Apoptin expression
cassette controlled by human cytomegalovirus (HCMV) promoter was obversely inserted to form AD55-Apoptin. ITR is the inverted terminal
repeat sequence. B. Detection of E1A levels of recombinant oncolytic adenoviruses. L-02, Huh-7 and PLC was infected with ONYX-015, AD55 and
AD55-Apoptin at the MOI of 5, after 48 hours, Western Blotting was conducted to detect E1A protein expression, b-actin was used as a protein
loading control. C. 3.5 × 10
5 cells were plated into six-well plates. After 24 h, the cells were infected with 10 MOIs of AD55-Apoptin or AD55 or
ONYX-015 or ZD55-EGFP, respectively. After an additional 48 h, medium and cells were scraped into 1.5 ml Eppendorf tube and subjected to
three-thaw cycles. The collected supernatant was tested for virus production by standard TCID50 assay on 293 cells. Progeny viruses from 1 MOI
of virus were calculated. The results were the average of two independent experiments. D. Huh-7 and QSG-7701 cells were infected with AD55
or AD55-Apoptin at the MOI of 10 for 24, 48 and 96 hours, respectively. The total RNA was collected at the indicated time and reverse
transcripted into cDNA, then a real time quantitative PCR was done with the Apoptin or GAPDH primers.
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015 at a MOI of 5 for 48 h. The results clearly
addressed that AD55-Apoptin induced more remarkable
apoptotic morphological changes such as chromatin
condensation, formation of apoptotic body than that of
AD55 and ONYX-015 in Huh-7 cells but much less in
normal cells L-02 and WI38 in Figure 4. Moreover, the
other HCC cells such as PLC, HepG2 also showed the
apoptic cells treated with AD55-Apoptin, although it did
not seem obvious.
Figure 2 MTT assay detected cell viability of tumor cells and normal cells infected with increasing MOIs of recombinant oncolytic
adenovirus. A.Tumor cells were infected with ONYX-015, AD55 and AD55-Apoptin at the increasing MOIs (0.1, 1, 10), after 4 days, cell viability
was determined by MTT assay. B. Cell viability of normal cells (L-02, WI38, QSG-7701) infected with the above three different viruses, Datas were
shown as means ± SD (error bars) of triplicate experiments,* p < 0.05, compared with the AD55 treatment group.
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assay showed AD55-Apoptin can strongly induce the
apoptosis of Huh-7 cell compared to the other groups
in Figure 5. These data further confirmed the mechan-
ism of apoptosis can account for the anti-hepatoma
effects of AD55-Apoptin.
Antitumor efficacy of AD55-Apoptin in nude mice
To determine the antitumor activity of AD55-Apoptin
in vivo, a model of Huh-7 human liver tumor xenograft
was established in nude mice. When the tumors volume
reached to about 425 mm
3 which was more closed to
advanced HCC, PBS, AD55-Apoptin, AD55 and ONYX-
015 (3 × 10
8 PFU/dose) in 100 μl were injected intratu-
morally everyday by five times totally. Mice treated with
AD55-Apoptin exhibited statistically significant suppres-
sion of hepatocarcinoma development compared to
ONYX-015 (P < 0.05) or AD55 (P < 0.05) or PBS trea-
ted mice ((P < 0.01)) in Figure 6, although the antitumor
effect of ONYX-015 was superior to that of AD55,
which was consistent with the related MTT results in
vitro.
Evidence for AD55-Apoptin on tumor growth inhibition in
vivo
Hematoxylin and eosin (H&E) staining showed that
injections of AD55-Apoptin caused profound cell death
and necrosis symptom in tumor mass than that of
ONYX-015 or AD55, the PBS-treated group as a nega-
tive control (Figure 7A). The results of
Figure 3 AD55-Apoptin showed the selective anti-hepatoma effect in a time-dependent manner. A. Tumor cells (Huh7, PLC, Hep3B,
HepG2) were infected with ONYX-015, AD55 and AD55-Apoptin at the MOI of 10 for 1,2,3,4 days, respectively. At the indicated time, cell viability
was determined by MTT assay. B. According to the above similar method, the cell viability of normal cells infected with various viruses was
detected by MTT assay. Datas are presented as means ± SD (error bars) of triplicate experiments.
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Page 7 of 12Figure 4 Hoechst 33342 stanning for the apoptotic cells infected with the various viruses. Tumor cells or normal cells were infected with
AD55, AD55-Apoptin and ONYX-015 at the MOI of 5, respectively. After 48 hours, cells were incubated with Hoechst 33342 for 30 min and
observed under a fluorescence microscope (arrows indicated apoptotic cells). (Original magnification: ×200).
Figure 5 Mechanism of apoptosis is mediated by AD55-Apoptin in Huh-7 cells. Huh-7 cells infected with ZD55-EGFP or ONYX-015 or AD55
or AD55-Apoptin at the MOI of 10, respectively. After 48 hours, the cells were trypsinized and washed once with complete medium. Aliquots of
cells (5 × 10
5) were resuspended in 500 ml of binding buffer and stained with fluorescein isothiocyanate (FITC)-labeled annexin V kit, according
to the manufacturer’s instructions. A fluorescence-activated cell-sorting assay was performed immediately after staining. Mean ± SD;*.p < 0.01,
compared with AD55 treated group.
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Page 8 of 12Figure 6 Antitumor effect of AD55-Apoptin in nude mice xenograft model. Tumors were established by injecting Huh-7 cells
subcutaneously into the right flank of nude mice. When tumors reached about 425 mm
3, the mice were divided into four groups (n = 8) and
treated with five consecutive daily intratumoral injections of PBS or ONYX-015, AD55 and AD55-Apoptin at 3 × 10
8 PFU/dose everyday per nude
mice The 16
th day was the starting time of treatment. Datas were showed as means ± SD.
Figure 7 Evidences of antitumor efficacy of AD55-Apoptin in vivo. The pathologic detection by H.E, IHC and TUNEL staining assay were
performed. Subcutaneous Huh-7 tumors receiving various treatments were harvested on the 4th day after infection with viruses. Tumor sections
were treated as described above methods and materials. A. H.E staining assay. partial area of necrosis have been detected in the sections treated
with ONYX-015, AD55, AD55-Apoptin (indicated with the black arrows), compared to the PBS group(×100, original magnification). B. The
adenovirus hexon protein as an indicator of adenovirus in vivo was detected by IHC analysis as described above methods and materials. (×400,
original magnification). Hexon expression was positive (arrows indicated) in three groups treated with ONYX-015 or AD55 or AD55-Apoptin,
respectively. C. The terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay for detection of apoptotic cells in
tumor sections treated with PBS or the above various recombinant viruses (×400, original magnification). The black arrows indicated the obvious
apoptotic cells in the AD55-Apoptin treated group than that of AD55, ONYX-015 or PBS treated group.
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expression in tumor cells treated with AD55-Apoptin
but less positive in those treated with ONYX-015 or
AD55, the PBS-treated group was as negative control
(Figure 7B). Additionally, terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling (TUNEL)
staining further confirmed AD55-Apoptin induced more
obvious apoptotic cells (arrows indicated the brown
stained cells)sis in tumors whereas the apoptotic cells in
the group treated with ONYX-015 or AD55 were less
(Figure 7C).
Moreover, the mice liver function was examined one
month later after injection of PBS or ONYX-015 or
AD55-Apoptin respectively. The results demonstrated
that AD55-Apoptin had less impair effect on the liver
function by AST/ALT at 1.22 than ONYX-015 at 3.00(p
< 0.01) or even less than on treatment PBS group at
2.80(p < 0.01) (the detailed data not show). It further
demonstrated the safety of AD55-Apoptin on hepatocar-
cinoma therapy.
Discussion
The conditionally replicating oncolytic adenovirus is
exploited as a powerful agent for cancer therapy. The
most famous and researched is ONYX-015 which
already entered phase III clinical trial. Originally,
ONYX-15 was convinced selective replication in p53-
deficient tumor cells by thinking of viral E1b-55 kDa
protein switch off p53 [29]. But later more exceptions
or even contraries were found, such as ONYX-15 repli-
cated in U87 cells(p53
+) [30] as same as wild type did.
Although recently it was clarified that late viral RNA
export, rather than p53 inactivation, determines ONYX-
015 tumor selectivity [7], what’s more, a novel pathway
showed that the adenoviral protein, E4-ORF3, induced
histone methylation silences p53 targets [31]. But the
precise mechanism remains unknown. Furthermore
ONYX-015 still can replicate in primary hepatocytes
[7,32], consistent with our studies shown ONYX-015
can kill normal hepatocellular cells L-02 to some extent
(Figures 3 and 4).
Hence, in our study we replaced the native E1A pro-
moter with HCC specific promoter AFP promoter based
on ZD55 to make it more specifically replicate in hepa-
tocarcinoma cells. Our data showed that AD55 induced
much less damage on normal cells although at the
expense of some killing effect on tumor cells(Figure 3).
Even though it is known that cellular promoters do not
keep the proper fidelity in the viral genome. Low levels
of E1a protein may be sufficient for replication, thus
preventing specificity [33,34]. Therefore, in order to aug-
ment the antitumor effect but also keep the specificity
to the fullest extent of AD55, it is worthwhile to explore
a gene which possesses not only remarkable antitumor
features but also high tumor selecting. Apoptin as a
small apoptosis-inducing protein derived from chicken
anemia virus (CAV) has such properties.
Piles of reports have shown Apoptin induced the
selective death in various of human tumor cells includ-
ing melanoma, hepatoma, lymphoma, cholangiocarci-
noma, colon carcinoma, breast and lung cancer and
other types [35,36], even also in SV40-transformed
fibroblasts or UV-irradiated cells from individuals with
hereditary cancer-prone syndromes [13,37], but not in
normal cells, non-transformed cells such as human
endothelial cells, hepatocytes, hematopoietic stem cells,
keratinocytes, or smooth muscle cells [38]. Furthermore
the efficiency and safety of Apoptin on tumor therapy
were further testified in vivo by mice models [21,39].
Previous studies have well established Apoptin induces
cell death though the intrinsic mitochondrial pathway.
Apoptin can trigger the release of cytochrome c which
at last induces caspase 9 activation via combination with
Apaf-1 [16,40]. While the mechanism by which Apoptin
is able to distinguish between tumor and normal cells
remains unclear, but seems to correlate with its cellular
localization. Recently, Maddika et al indicated PI3K/
Akt/CDK2 pathway plays a pivotal role in Apoptin-
induced apoptosis. Their results revealed that Apoptin
interacts with PI3K/Akt results in its nuclear transloca-
tion and sustained activation which initiates apoptosis
instead of a survival response, on the other hand, the
activated Akt further activates CDK2 which directly
phosphorylates apoptin to lead to the accumulation of
apoptin in nuclear, this is crucially required for Apop-
tin-induced cell death. The fact suggested that inhibitors
of PI3-kinase or Akt inhibited CDK2 activation hence to
protect cells from Apoptin-induce cell death [41,42].
Considering the abnormal PI3K/Akt activation in var-
ious type of cancer cells [43], this at least can partially
elucidate the specificity and efficiency of apoptin on kill-
ing tumor cells. Nevertheless, more details still need to
be explored.
Additionally, some other properties of apoptin make
it more attractive for tumor gene therapy, including
the ability to induce tumor-specific apoptosis indepen-
dently of p53 [14] which is deficient in many cancers
that are resistant to chemotherapeutic agent. Another
is that in certain tumor cell lines it mediated cell death
that is independent of the Bcl-2 status and even stimu-
lated by Bcl-2 [16], although the role of Bcl-2 in Apop-
tin-induced apoptosis is still a matter of debate. The
apparent controversy as to the role of Bcl-2 proteins
may arise from the differential involvement of Nur77,
in Apoptin-induced cell death. It has been shown that
Nur77 can bind to Bcl-2 and change its properties
from an anti-apoptotic to a pro-apoptotic molecule,
leading to the activation of mitochondrial death
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types at very varying levels, this might explain the
opposite effects of Bcl-2 on Apoptin-induced cell
death. Besides, Maddika et al indeed proposed a role
of Nur77 in Apoptin mediated apoptosis [45]. Based
on above all, Apoptin is bona fide a promising candi-
date for our trial.
As shown in our study, AD55-Apoptin demonstrated
a much stronger capability to induce apoptosis of hepa-
tocarcinoma cells than that of ONYX-015 and AD55,
however, it had no or little impair on normal cells (Fig-
ures 2, 3, 4A), no matter in a dose dependent manner
(Figure 2) or time dependent manner (Figure 3). More-
over, the efficiency and safety of AD55-Apoptin were
demonstrated in HCC cell line Huh-7 xenograft models
(Figure 6). It can even inhibit the hepatoma tumor
growth with a large volume up to about 425 mm
3 in
nude mice xenograft model because a proper beginning
tumor volume in a routine xenograft model at volume
of 80-120 mm
3 or a litter bigger of 100-150 mm
3 was
sensitive and effective to the recombinant adenovirus.
Pathological examination further confirmed the replica-
tive progeny virions of AD55-Apoptin expressed the
adenovirus hexon protein specifically in xenograft can-
cer cells and induced more apoptosis than AD55 and
ONYX-015(Figure 7). In view of connection between
Apoptin and PI3K/Akt, some antitumor chemotherapeu-
tic agents such as methotrexate or docetaxel [46] or
paclitaxel [47] which sensitize tumor cells for apoptosis
under prolonged nuclear Akt/CDK2 activation may can
be used together with AD55-Apoptin to get a even bet-
ter effect.
Conclusion
AD55-Apoptin was successfully generated and more
powerful and safe on hepatocarcinoma therapy than
AD55 or even classical ONYX-015. It throws some light
on the strategy of Cancer Targeting Gene-Viro-Therapy
and may provide some referenced value for clinic cancer
therapeutic research.
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